Pentraxin 3 is reduced in bipolar disorder

Bipolar Disorders

Volumn 17, Issue 4, 2015, Pages 409-414

  Dickerson, Faith ^a   Stallings, Cassie ^a   Origoni, Andrea ^a   Katsafanas, Emily ^a   Schweinfurth, Lucy Ab ^a   Savage, Christina Lg ^a   Khushalani, Sunil ^a   Yolken, Robert ^b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bipolar disorder; Innate immunity; Pentraxin 3; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; LITHIUM SALT; MOOD STABILIZER; NEUROLEPTIC AGENT; PENTRAXIN 3; BIOLOGICAL MARKER; C REACTIVE PROTEIN; SERUM AMYLOID P;

ADULT; AGE; AGED; ARTICLE; BIPOLAR DISORDER; BODY MASS; CONTROLLED STUDY; DEMOGRAPHY; EDUCATIONAL STATUS; FEMALE; GENDER; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; MOTHER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RACE; SCHIZOPHRENIA; SMOKING; BLOOD; IMMUNOLOGY; MIDDLE AGED; PSYCHOLOGY; REFERENCE VALUE;

ADULT; BIOMARKERS; BIPOLAR DISORDER; C-REACTIVE PROTEIN; FEMALE; HUMANS; IMMUNITY, INNATE; MALE; MIDDLE AGED; REFERENCE VALUES; SCHIZOPHRENIA; SERUM AMYLOID P-COMPONENT;

EID: 84930393405     PISSN: 13985647     EISSN: 13995618     Source Type: Journal    
DOI: 10.1111/bdi.12281     Document Type: Article

References (39)

1. Gershon ES, Alliey-Rodriguez N, Liu C. After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. Am J Psychiatry 2011; 168: 253-256.
2. Kerner B. Genetics of bipolar disorder. Appl Clin Genet 2014; 7: 33-42.
3. Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Mol Cell Neurosci 2013; 53: 52-62.
4. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011; 25: 1206-1213.
5. Hamdani N, Tamouza R, Leboyer M. Immuno-inflammatory markers of bipolar disorder: a review of evidence. Front Biosci 2012; 4: 2170-2182.
6. O'Brien SM, Scully P, Scott LV, Dinan TG. Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord 2006; 90: 263-267.
7. Ortiz-Domínguez A, Hernández ME, Berlanga C et al. Immune variations in bipolar disorder: phasic differences. Bipolar Disord 2007; 9: 596-602.
8. Huang TL, Lin FC. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 370-372.
9. Goldstein BI, Kemp DE, Soczynska JK, McIntyre RS. Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry 2009; 70: 1078-1090.
10. Soderlund J, Olsson SK, Samuelsson M et al. Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder. J Psychiatry Neurosci 2011; 36: 114-118.
11. Barbosa IG, Machado-Vieira R, Soares JC, Teixeira AL. The immunology of bipolar disorder. Neuroimmunomodulation 2014; 21: 117-122.
12. Foldager L, Kohler O, Steffensen R et al. Bipolar and panic disorders may be associated with hereditary defects in the innate immune system. J Affect Disord 2014; 164: 148-154.
13. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu Rev Immunol 2010; 28: 157-183.
14. Daigo K, Mantovani A, Bottazzi B. The yin-yang of long pentraxin PTX3 in inflammation and immunity. Immunol Lett 2014; 161: 38-43.
15. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Sem Arthritis Rheumatism 2009; 39: 38-54.
16. Baruah P, Propato A, Dumitriu IE et al. The pattern recognition receptor PTX3 is recruited at the synapse between dying and dendritic cells, and edits the cross-presentation of self, viral, and tumor antigens. Blood 2006; 107: 151-158.
17. Hamdani N, Doukhan R, Kurtlucan O, Tamouza R, Leboyer M. Immunity, inflammation, and bipolar disorder: diagnostic and therapeutic implications. Curr Psychiatry Rep 2013; 15: 387.
18. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010; 12: 638-646.
19. Benros ME, Waltoft BL, Nordentoft M et al. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMA Psychiatry 2013; 70: 812-820.
20. First M, Gibbon M, Spitzer RL, Williams JBW. User's Guide for the SCID-I, Structured Clinical Interview for DSM IV Axis I Disorders. New York, NY: Biometrics Research, 1996.
21. First M, Gibbon M, Spitzer RL, Williams JBW. Structured Clinical Interview for DSM-IV Disorders, Non-Patient Edition. New York, NY: Biometrics Research, 1998.
22. Randolph C, Tierney MC, Mohr E, Chase TN. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998; 20: 310-319.
23. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276.
24. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 1978; 133: 429-435.
25. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967; 6: 278-296.
26. Rubin D. Multiple imputation after 18+ years. J Am Stat Ass 1996; 91: 473-489.
27. Brambilla P, Bellani M, Isola M et al. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry 2014; 4: e406.
28. Severance EG, Gressitt KL, Stallings CR et al. Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia. Schizophr Res 2013; 148: 130-137.
29. Altamura AC, Buoli M, Pozzoli S. Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: comparison with schizophrenia. Psychiatry Clin Neurosci 2014; 68: 21-36.
30. Oliveira J, Hamdani N, Etain B, et al. Genetic association between a 'standing' variant of NOD2 and bipolar disorder. Immunobiology 2014; 219: 766-771.
31. Oliveira J, Hamdani N, Busson M et al. Association between toll-like receptor 2 gene diversity and early-onset bipolar disorder. J Affect Disord 2014; 165: 135-141.
32. Altamura AC, Mundo E, Cattaneo E et al. The MCP-1 gene (SCYA2) and mood disorders: preliminary results of a case-control association study. Neuroimmunomodulation 2010; 17: 126-131.
33. Barden N, Harvey M, Gagne B et al. Analysis of single nucleotide polymorphisms in genes in the chromosome 12Q24.31 region points to P2RX7 as a susceptibility gene to bipolar affective disorder. Am J Med Genet B 2006; 141B: 374-382.
34. Bassi N, Ghirardello A, Blank M et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheumat Dis 2010; 69: 1704-1710.
35. Bozza S, Campo S, Arseni B et al. PTX3 binds MD-2 and promotes TRIF-dependent immune protection in aspergillosis. J Immunol 2014; 193: 2340-2348.
36. Lech M, Rommele C, Kulkarni OP et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS ONE 2011; 6: e20118.
37. Hamdani N, Daban-Huard C, Lajnef M et al. Relationship between Toxoplasma gondii infection and bipolar disorder in a French sample. J Affect Disord 2013; 148: 444-448.
38. Severance EG, Gressitt KL, Yang S et al. Seroreactive marker for inflammatory bowel disease and associations with antibodies to dietary proteins in bipolar disorder. Bipolar Disord 2014; 16: 230-240.
39. Wadee AA, Kuschke RH, Wood LA, Berk M, Ichim L, Maes M. Serological observations in patients suffering from acute manic episodes. Hum Psychopharmacol 2002; 17: 175-179.